KPT 9274

Drug Profile

KPT 9274

Alternative Names: ATG-019; KPT-9274

Latest Information Update: 31 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Karyopharm Therapeutics
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Nicotinamide phosphoribosyltransferase inhibitors; P21 activated kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Non-Hodgkin's lymphoma; Solid tumours

Most Recent Events

  • 24 May 2018 Karyopharm Therapeutics and Antengene agree to co-promote and co-develop Selinexor in China, Macau, Taiwan, Hong Kong, South Korea and the ASEAN countries
  • 21 Apr 2018 Pharmacodynamics data from a preclinical study presented at the 109th Annual Meeting of the American Association for Cancer Research (AACR-2018)
  • 08 Sep 2017 Preliminary efficacy and adverse events data from a phase I trial in Solid tumours and Non-Hodgkin's lymphoma presented at the 42nd European Society of Medical Oncology Congress (ESMO-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top